Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase II interventional study in order to assess efficacy and safety
of single agent ublituximab as initial therapy for FL (Follicular lymphoma) and MZL (Marginal
zone lymphoma ) with response driven addition of umbralisib for suboptimal response.